In vitro and in vivo evaluation of antitumor drug-loaded aptamer targeted single-walled carbon nanotubes system

Current Pharmaceutical Biotechnology

Volumn 14, Issue 13, 2014, Pages 1105-1117

  Zhang, Huijuan ^a   Hou, Lin ^a   Jiao, Xiaojing ^a   Ji, Yandan ^a   Zhu, Xiali ^a,b   Li, Hongji ^a   Chen, Xiaozhe ^a   Ren, Junxiao ^a   Xia, Yadan ^a   Zhang, Zhenzhong ^a  

^a ZHENGZHOU UNIVERSITY   (China)

^b HENAN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Aptamer; Chemo photothermal synergistic effect; Single walled carbon nanotubes; Tumor targeting

Indexed keywords

APTAMER; CARBON NANOTUBE; DOXORUBICIN; SULFORHODAMINE B; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; PEPTIDE APTAMER;

ADSORPTION KINETICS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOCOMPATIBILITY; CELL CYCLE PARAMETERS; CELL FUNCTION; CELLULAR DISTRIBUTION; CELLULAR UPTAKE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; EVALUATION STUDY; EXPERIMENTAL STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PHYSICAL PHENOMENA; QUANTITATIVE ASSAY; TUMOR XENOGRAFT; ZETA POTENTIAL; ANIMAL; AREA UNDER THE CURVE; CELL CYCLE; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; MOUSE; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; APTAMERS, PEPTIDE; AREA UNDER CURVE; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; HUMANS; MICE; NANOTUBES, CARBON; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903733502     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201015666140408123710     Document Type: Article

References (35)

1. Athulya, A.; Prashanti, J.; Remya, N.; Srivani, V.; Yutaka, N.; Yasuhiko, Y.; Toru, M.; Sakthi, K. AS1411 aptamer tagged PLGAlecithin- PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol. Bioengin., 2012, 109(11), 2920-2931.
2. Ruibin, L.; Ren'an, W.; Liang, Z.; Minghuo, W.; Ling, Y.; Hanfa, Z. P-glycoprotein antibody functionalized carbon nanotube overcomes the multidrug resistance of human leukemia cells. Amer. Chemical Soc., 2010, 4(3), 1399-1408.
3. Huijuan, Z.; Chengqun, C.; Lin, H.; Nan, J.; Jinjin, S.; Qianhua, F.; Zhenzhong, Z. Targeting and hyperthermia of doxorubicin by the delivery of single walled carbon nanotubes to EC-109 cells. J. Drug Target., 2013, 21(3), 312-319.
4. Chengqun, C.; Huijuan, Z.; Lin H.; Jinjin, S.; Lei, W.; Chaofeng, Z. Single-walled carbon nanotubes mediated neovascularity targeted anti-tumor drug delivery system. J. Pharm. Pharmaceut. Sci., 2013, 16(1), 40-51.
5. Zhou, F.; Wu, S.; Song, S.; Chen, W.R.; Resasco, D.E.; Xing, D. Antitumor immunologically modified carbon nanotubes for photothermal therapy. Biomaterials, 2012, 33, 3235-3242.
6. Ravi, S.; Davide, P.; Lara, L.; Giorgia, P.; Cédric, K.; Maurizio, P.; Alberto, B.; Kostas K. Tissue Biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. PNAS, 2006, 103(9), 3357-3362.
7. Jiao, Z.; Juanping, L.; Yuhong, N.; Jishan, L.; Jinfeng, Y. Affinity and fluorescent detection of surfactants/ssDNA and single-walled carbon nanotube. Trans. Nonferrous Met. Soc. China, 2013, 23, 456-461.
8. Liu, X.; Tao, H.; Yang, K.; Zhang, S.; Lee, S.T.; Liu, Z. Optimization of surface chemistry on single-walled carbon nanotubes for in vivo photothermal ablation of tumors. Biomaterials, 2011, 32, 144-151.
9. KyungMi, S.; Seonghwan, L.; Changill, B. Aptamers and their biological applications. Sensors, 2012, 12, 612-631.
10. Zeyu, X.; Omid, C.; Farokhzad. Aptamer-functionalized nanoparticles for medical applications: challenges and opportunities. Amer. Chemical Soc., 2012, 6(5), 3670-3676.
11. Ellington, A.D.; Szostak, J.W. In vitro selection of RNA molecules that bind specific ligands. Nature, 1990, 346, 818-822.
12. Tuerk, C.; Gold, L. Systematic evolution of ligands by exponential enrichment - RNA ligands to bacteriophage-T4 DNApolymerase. Science, 1990, 249, 505-510.
13. Beaudry, A.A.; Joyce, G.F. Directed evolution of an RNA enzyme. Science, 1992, 257, 635-641.
14. Fang, X.H.; Tan, W.H. Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc Chem Res., 2010, 43, 48-57.
15. Li, D.; Song, S.; Fan, C. Target-responsive structural switching for nucleic acid-based sensors. Acc. Chem. Res., 2010, 43, 631-641.
16. KuanCan, L.; BaoShun, L.; XiaoPeng, L. Aptamers: A promising tool for cancer imaging, diagnosis, and therapy. J. Cellular Biochem., 2013, 114, 250-255.
17. Oh, S.S.; Plakos, K.; Lou, X.H.; Xiao, Y.; Soh, H.T. In vitro selection of structure-switching, self-reporting aptamers. Proc. Natl. Acad. Sci. U.S.A., 2010, 107, 14053-14058.
18. Hang, X.; Ngo, Y.W.; Yu, X.; Yi, L. DNA aptamer functionalized nanomaterials for intracellular analysis, cancer cell imaging and drug delivery. Curr. Opin. Chemical Biol., 2012, 16, 429-435.
19. Bates, P.J.; Laber, D. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol., 2009, 86(3), 151-164.
20. López, C.D.; Jiménez, E.; You, M.; Gulbakan, B.; Tan, W. Aptamers: Turning the spotlight on cells. Wiley interdisciplinary reviews. Nanomed Nanobiol., 2011, 3(3), 328-340.
21. Ray, P.; White, R.R. Aptamers for targeted drug delivery. Pharmaceuticals, 2010, 3(6), 1761-1778.
22. Soundararajan, S.; Wang, L.; Sridharan, V. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4- 11 leukemia cells. Leuk. Lymphoma., 2009, 76(5), 984-991.
23. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev., 2004, 56, 185-229.
24. Fabien, M.; Philippe, B. AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr. Opin. Mol. Ther., 2010, 12(1), 107-114.
25. Jones, D.; Dobinson, D.; Doran, B.; Odumeru, T.; Shah, K.; Kuijper, S.; Green, C.; Courtenay-Luck, N.; McLaughlin, F.; Djeha, H. AS1411, a novel anti-nucleolin aptamer, shows synergy with other anti-cancer drugs in vitro and in vivo in AML models. Am. Assoc. Cancer. Res. Ann. Meet., 2008, 99, 5689.
26. Bianco, A.; Kostarelos, K.; Partidos, C.D.; Prato, M. Biomedical applications of functionalised carbon nanotubes. Chem. Commun. (Camb)., 2005, 7, 571-577.
27. Que-Gewirth, N.S.; Sullenger, B.A. Gene therapy progress and prospects: RNA aptamers. Gene Ther., 2007, 14, 283-291.
28. Yun, T.; Girvan, A.C.; Casson, L.K.; William, M.; Pierce, W.M.; Mingwei, Q.; Thomas, S.D.; Bates, P.J. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res., 2007, 7(1), 10491-10502.
29. Christopher, R.I.; Kelland, L.R. Discovery and development of anticancer aptamers. Mol.Cancer Ther., 2006, 5(12), 2957-2962.
30. Satoru, K.; Paul, V.; Derek, T.; Kai, M.; Xianmin, X.; Qiangrong, L. Transcription factor GATA4 inhibits doxorubicin-induced autophagy and cardiomyocyte death. Biologic. Chem., 2010, 285, 793-804.
31. Gangjun, D.; Haihong, L.; Mei, W.; Shuo, Z.; Xianchuang, W.; Linlin, L.; Liyan, J.; Lijuan, Y. Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing eVects on HIF-1 in tumor and normal cells. Cancer Chemother. Pharmacol. 2010, 65, 277-287.
32. Gianni, L.; Salvatorelli, E.; Minotti, G. Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes. Cardiovasc. Toxicol., 2007, 7(2), 67-71.
33. Michael, B.K.; Jiri, B. Cell-cycle checkpoints and cancer. Nature, 2004, 432(18), 316-323.
34. Gary, K.S.; Manish, A.S. Targeting the cell cycle: A new approach to cancer therapy. J. Clinic. Oncol., 2005, 23(36), 9408-9421.
35. Dewey, W.C.; Hopwood, L.E.; Sapareto, S.A.; Gerweck, L.E. Cellular responses to combinations of hyperthermia and radiation. Radiology, 1977, 123(2), 463-474.